Twist Bioscience Corp expected to post a loss of $1.12 a share - Earnings Preview
03/05/2023 16:05
* Twist Bioscience Corp TWST.OQ TWST.O is expected
to show a
rise in quarterly revenue when it reports results on May 5.
* The South San Francisco California-based company is
expected to
report a 17.8% increase in revenue to $56.694 million from
$48.13 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. The company's guidance on
March 14 2023, for the period ended March 31, was for revenue of
$56.500 million.
* Refinitiv's mean analyst estimate for Twist Bioscience
Corp is
for a loss of $1.12 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Twist
Bioscience
Corp is $30.5, above its last closing price of $11.49.
The company's guidance on March 14 2023 for the period ended
March 31 was for gross profit margin of USD30%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -1.12 -1.13 -0.74 Beat 34.7
Sep. 30 2022 -1.25 -1.25 -0.91 Beat 27.1
Jun. 30 2022 -1.31 -1.31 -1.08 Beat 17.5
Mar. 31 2022 -1.28 -1.28 -1.13 Beat 11.5
Dec. -1.07 -1.06 -0.91 Beat 14.5
31 2021
Sep. 30 2021 -0.80 -0.79 -0.84 Missed -5.8
Jun. 30 2021 -0.75 -0.75 -0.78 Missed -3.8
Mar. 31 2021 -0.77 -0.77 -0.78 Missed -1.6
This summary was machine generated May 3 at 15:05 GMT. All
figures in US dollars unless otherwise stated